Previous 10 | Next 10 |
2023-11-28 06:45:51 ET More on Argenx, Halozyme, etc. argenx Q3: Navigating The Highs And Hurdles Of A Market Odyssey (Rating Upgrade) Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcr...
2023-11-17 09:26:34 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Q3 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited 2023 Q3 - Results - Earnings Call Presentation Teva: Focus On Innovation And Growth Means The Time...
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis PR Newswire VYVGART® SC Now Approved for Subcutaneous Administration, Adding to the Already Approved IV Administration SAN DI...
2023-11-16 08:04:42 ET More on Argenx SE argenx SE (ARGX) Q3 2023 Earnings Call Transcript argenx: Efgartigimod Is Not Just A Drug, A Cornerstone Argenx SE GAAP EPS of -$1.25 beats by $0.18, total operating income of $339.84M beats by $38.12M Immunovant drive...
2023-11-15 20:26:43 ET Summary Halozyme's Q3 2023 earnings showed robust performance, with a 41% YoY increase in product sales and a 15% YoY growth in royalty revenue. The company's strategic moves, including a $250M share repurchase plan and new partnerships, highlight its commit...
2023-11-08 05:19:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly...
2023-11-06 20:18:11 ET Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer...
2023-11-06 16:09:27 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q3 Non-GAAP EPS of $0.75 beats by $0.04 . Revenue of $216M (+3.4% Y/Y) in-line. Sees 2023 Non-GAAP diluted earnings per share of $2.70 to $2.80. Sees 2023 EBITDA of $430 million to $44...
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and...
2023-11-06 08:23:39 ET More on Acumen Pharmaceuticals, Halozyme Therapeutics, etc. Navigating Acumen's Alzheimer's Risk And Reward Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA ...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...